Abstract CT094: Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC
Bibliographic record
Abstract
Abstract Background: At the first planned interim analysis of the phase 3 ADRIATIC study (NCT03703297), consolidation D significantly improved the dual primary endpoints of overall survival (OS; HR 0.73; 95% CI 0.57-0.93; p=0.0104) and progression-free survival (PFS; HR 0.76; 95% CI 0.61-0.95; p=0.0161) vs P in patients (pts) with LS-SCLC with no progression after cCRT. Although PD-L1 is not currently a validated immunotherapy biomarker in SCLC (unlike NSCLC) and is generally expressed at low levels in this setting, PD-L1 was evaluated as a potential biomarker in ADRIATIC. Methods: Pts with stage I-III LS-SCLC (stage I/II inoperable), WHO performance status 0/1, and no progression after cCRT, were randomized 1-42 days post cCRT to D (n=264), D + tremelimumab (n=200; arm remains blinded), or P (n=266). The VENTANA PD-L1 (SP263) immunohistochemistry assay was used for central retrospective testing of pre-cCRT tissue samples. OS and PFS were assessed in the PD-L1-evaluable population and in subgroups with PD-L1 expression ≥1% on tumor cells (TC) and/or immune cells (IC) (secondary endpoint) and <1% on TC and IC (data cutoff: Jan 15, 2024). Results: Among 162 (61.4%) and 171 (64.3%) pts in the D and P arms who were evaluable for PD-L1, improvements in OS (HR [D vs P] 0.73 [95% CI 0.53-0.99]) and PFS (HR 0.80 [0.60-1.06]) were of similar magnitude to those in the ITT population. Of the PD-L1-evaluable pts, 51.9% (84/162) in the D arm and 57.3% (98/171) in the P arm had PD-L1 TC or IC ≥1%. D appeared to improve OS and PFS vs P in subgroups with TC or IC ≥1% and with TC and IC <1% (Table), consistent with the ITT population. Conclusions: Among the PD-L1-evaluable population in ADRIATIC, 54.7% (182/333) of pts had PD-L1 TC or IC ≥1%. Consolidation D appeared to improve OS and PFS vs P irrespective of PD-L1 expression based on a cutoff of 1% on TC and/or IC, further supporting consolidation D as the new standard of care in pts with LS-SCLC with no progression after cCRT. Citation Format: Christine Hann, Ying Cheng, David Spigel, Byoung Chul Cho, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Qiming Wang, Reyes Bernabe, John Wen-Cheng Chang, Sema Sezgin Goksu, Lin Wu, Gyeong-Won Lee, Michael Thomas, Yuichiro Ohe, Frank Griesinger, Leah Szadkowski, Hema Gowda, Yashaswi Shrestha, Suresh Senan. Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT094.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.000 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".